Abstract
Recent evidence suggests that autophagy may favor fibrosis through enhanced differentiation of fibroblasts in myofibroblasts. Here, we sought to characterize the mediators and signaling pathways implicated in autophagy-induced myofibroblast differentiation. Fibroblasts, serum starved for up to 4 d, showed increased LC3-II/-I ratios and decreased SQSTM1/p62 levels. Autophagy was associated with acquisition of markers of myofibroblast differentiation including increased protein levels of ACTA2/αSMA (actin, α 2, smooth muscle, aorta), enhanced gene and protein levels of COL1A1 (collagen, type I, α 1) and COL3A1, and the formation of stress fibers. Inhibiting autophagy with 3 different class I phosphoinositide 3-kinase and class III phosphatidylinositol 3-kinase (PtdIns3K) inhibitors or through ATG7 silencing prevented myofibroblast differentiation. Autophagic fibroblasts showed increased expression and secretion of CTGF (connective tissue growth factor), and CTGF silencing prevented myofibroblast differentiation. Phosphorylation of the MTORC1 target RPS6KB1/p70S6K kinase was abolished in starved fibroblasts. Phosphorylation of AKT at Ser473, a MTORC2 target, was reduced after initiation of starvation but was followed by spontaneous rephosphorylation after 2 d of starvation, suggesting the reactivation of MTORC2 with sustained autophagy. Inhibiting MTORC2 activation with long-term exposure to rapamycin or by silencing RICTOR, a central component of the MTORC2 complex abolished AKT rephosphorylation. Both RICTOR silencing and rapamycin treatment prevented CTGF and ACTA2 upregulation, demonstrating the central role of MTORC2 activation in CTGF induction and myofibroblast differentiation. Finally, inhibition of autophagy with PtdIns3K inhibitors or ATG7 silencing blocked AKT rephosphorylation. Collectively, these results identify autophagy as a novel activator of MTORC2 signaling leading to CTGF induction and myofibroblast differentiation.
Keywords: AKT, ATG7, autophagy, connective tissue growth factor (CTGF), differentiation, fibroblast, fibrosis, MTORC2, myofibroblast, rapamycin
Abbreviations: 3-MA, 3-methyladenine; ACTA2, actin, α 2, smooth muscle, aorta; Ctl, control; DAPI, 4′, 6-diamidino-2-phenylindole; ECM, extracellular matrix; FBS, fetal bovine serum; GF, growth factor; iso, isotype control; LC3B, MAP1LC3B (microtubule-associated protein 1 light chain 3 β); LY, LY294002; N, normal growth medium; R, rapamycin; SS, serum-free (starvation) medium; T, TGFB1 (transforming growth factor, β 1); TUBA, tubulin, α; V, vehicle; W, wortmannin; WB, western blotting
Introduction
In most, if not all, organs, tissue repair follows a stereotypical sequence of events that includes the differentiation of resident fibroblasts and stromal cells into myofibroblasts. In turn, differentiated myofibroblasts produce increased amounts of extracellular matrix (ECM) components such as COL1A1 and COL3A1 and acquire a contractile phenotype through enhanced expression of ACTA2 and formation of stress fibers.1-3 Myofibroblasts are key effectors of tissue repair and, under the influence of appropriate extracellular signals, favor tissue remodeling and wound closure. In fibrotic disorders, persistent myofibroblast accumulation fuels inappropriate ECM deposition, contracture, tissue deformation, and loss of function.3-5 TGFB (transforming growth factor, β) is one of the first mediators shown to mediate both initiation and perpetuation of myofibroblast differentiation.3,6 TGFB gene and protein expression are increased in an array of fibrotic disorders including pulmonary fibrosis, liver cirrhosis, chronic renal failure, and systemic sclerosis.7-10 In the past decade, a large body of evidence has demonstrated that CTGF/CCN2, is another central mediator of myofibroblast differentiation and fibrosis. CTGF expression is activated downstream of TGFB-dependent SMAD signaling and various reports point to CTGF as a key activator of myofibroblast differentiation.11 Also, the secretion of CTGF enhances TGFB signaling through increased receptor and cell-surface binding and SMAD phosphorylation favoring an autocrine fibrogenic amplification loop.12 Increased expression of CTGF has also been reported in a wide variety of fibrotic conditions including liver, renal and pulmonary fibrosis, and systemic sclerosis.13-18 More recently, different reports have shown that, in certain systems, CTGF can induce and sustain myofibroblast differentiation and development of fibrosis through TGFB-independent pathways.19,20 The pathways that foster CTGF overexpression independently of TGFB-signaling remain incompletely characterized but appear to involve, at least in part, responses to stress and hypoxia.19-22
Autophagy is a highly conserved catabolic pathway activated in response to stress or starvation. During autophagy, damaged organelles and selected proteins are sequestered within autophagosomes and targeted for degradation following autophagosome-lysosome fusion as a means of sustaining metabolism. Autophagy is initiated by MTORC1 inhibition, which facilitates activation of the PIK3C3/VPS34-PIK3R4-AMBRA1 complex required for initiation of autophagosome formation.23 Recent studies have highlighted a correlation between dysregulated autophagy and the development of fibrosis.24 Both up- and downregulation of autophagy have been associated with fibrosis in various organs, highlighting the potentially diverse functional role that autophagy may play in the various phases of response to stress and tissue repair.24 In models of liver fibrosis, reduced autophagy was shown to prevent differentiation of hepatic stellate cells into myofibroblast-like cells, therefore leading to reduced fibrogenesis.25,26 Fibrogenic cells of kidney and lung origin have also been shown to rely on autophagy to maintain an activated and fibrogenic phenotype.26 However, the signaling pathways and central mediators linking autophagy to myofibroblast differentiation and fibrosis remain largely undefined. Whether autophagy leads to fibrosis or prevents the onset of fibrosis is probably, at least in part, related to the cell compartments that are engaging the autophagic response and the downstream signaling pathways that may be triggered by the autophagic program.
Here, we sought to characterize the impact of autophagy on myofibroblast differentiation. We report that, in fibroblasts, prolonged autophagy is associated with inhibition of MTORC1 activation and, unexpectedly, enhanced MTORC2 activation, which in turn triggers CTGF-dependent myofibroblast differentiation.
Results
Autophagy is central to myofibroblast differentiation induced by prolonged starvation
To evaluate the functional importance of growth factor deprivation in the simultaneous activation of autophagy and myofibroblast differentiation, human embryonic lung fibroblasts were exposed to serum-free (starvation) medium (SS). LC3-II/-I ratios increased rapidly in starved fibroblasts (Fig. 1A) and were further increased in the presence of bafilomycin A1, an inhibitor of vacuolar-type H+-ATPases essential for the acidification of autophagic vacuoles (Fig. 1B). Infection with a baculovirus vector expressing GFP-LC3B revealed enhanced accumulation of LC3+ puncta in starved fibroblasts, which was further increased by bafilomycin A1 (Fig. 1C). Protein levels of SQSTM1, an autophagic substrate, decreased after 4 h of starvation and remained low thereafter (Fig. 1D). Markers of autophagy in starved cells were increased compared with cells maintained in normal culture conditions for up to 7 d (Fig. S1A, S1B). Collectively, these results suggest a sustained enhanced autophagic flux in serum-starved fibroblasts.27
We then evaluated whether markers of myofibroblast differentiation3 were modulated in association with autophagy. Protein levels of ACTA2 increased significantly after 4 d of serum starvation (Fig. 1E). After 4 d, serum-starved fibroblasts also showed enhanced ACTA2 protein levels and the presence of organized stress fibers by immunofluorescence microscopy (Fig. 1F). COL1A1 and COL3A1 mRNA levels (Fig. 1G) and proCOL1A1 protein levels (Fig. S1C) also increased in starved fibroblasts. Similarly, in mouse embryonic fibroblasts and adult human lung fibroblasts, we found an association between increased autophagy upon long-term serum starvation and evidence of myofibroblast differentiation (Fig. S1D). Fibroblasts maintained in normal culture conditions for up to 7 d did not show evidence of myofibroblast differentiation (Fig. S1B).
To analyze the functional role of autophagy in myofibroblast differentiation, we inhibited the autophagic response in starved fibroblasts with 3-methyladenine (3-MA), wortmanmin (W) or LY294002 (LY).28 In starved cells these chemicals inhibit PtdIns3K.28-30 All 3 inhibitors prevented enhanced LC3-II/-I ratios upon starvation (Fig. 2A) and also prevented upregulation of ACTA2 (Fig. 2B and S2A, S2B) and pro-COL1A1 (Fig. S2C). Autophagy inhibition also prevented the formation of stress fibers and reduced collagen mRNA synthesis (Fig. 2C, D). Inhibiting autophagy through silencing of the key autophagic gene ATG731 prevented myofibroblast differentiation (Fig. 2E, F) further supporting the central role of autophagy in triggering pathways leading to myofibroblast differentiation. We also considered the potential role of cell death in our system. In previous work, we showed that WI-38 fibroblasts serum starved for up to 7 d maintained low levels of apoptosis and no sign of necrosis.32,33 Also, PARP cleavage, another read-out of apoptotic cell death, is not enhanced in fibroblasts serum starved for 4 or 7 d (Fig. S2D). Collectively, these results suggest that cell death-dependent pathways are unlikely contributors to the association between autophagy and myofibroblast differentiation.
TGFB-independent and CTGF-dependent pathways control autophagy-induced myofibroblast differentiation
We then sought to characterize the mediators implicated in autophagy-induced myofibroblast differentiation. TGFB is a classical inducer of myofibroblast differentiation,6 and fibrogenic signaling downstream of TGFB involves the SMAD family of transcriptional activators.34 To determine if TGFB signaling is implicated in autophagy-induced myofibroblast differentiation, SMAD2 phosphorylation was evaluated by immunoblotting in serum-starved fibroblasts. Serum starvation failed to induce SMAD2 phosphorylation, whereas exposure to recombinant TGFB1 induced strong SMAD2 phosphorylation (Fig. 3A and S3A). Since TGFB can trigger fibrogenic signals through noncanonical SMAD-independent pathways,6 we also evaluated ACTA2 protein levels in serum-starved fibroblasts in the presence of antibodies neutralizing all TGFB1, 2 and 3 isoforms or isotype-matched control. Recombinant TGFB1 was used as a positive control for the neutralizing capacity of the anti-TGFB antibody. Anti-TGFB neutralization failed to reduce myofibroblast differentiation in starved fibroblasts (Fig. 3B lane 2) but effectively dampened ACTA2 overexpression induced by recombinant TGFB1 (Fig. 3B lane 5). Collectively, these results suggest that autophagy elicits myofibroblast differentiation largely through TGFB-independent pathways.
CTGF is increasingly recognized as a downstream integrator of various fibrogenic stimuli and a specific marker of fibrotic tissues.35,36 Hence, we evaluated if starvation modulates CTGF mRNA and protein levels. Prolonged starvation led to a significant increase in CTGF mRNA level (Fig. 3C). There was an initial decrease in cellular CTGF protein levels upon initiation of starvation. This was followed, after 2 and 4 d of starvation, with a progressive increase in CTGF levels (Fig. 3D and S3B). Also, extracellular release of CTGF rose over time in serum-starved fibroblasts (Fig. 3E). We then investigated the functional importance of CTGF in starvation-induced myofibroblast differentiation. Blocking CTGF upregulation with siRNAs significantly lowered ACTA2 protein levels in autophagic fibroblasts (Fig. 3F), establishing a central role for CTGF in myofibroblast-differentiation triggered by starvation.
To test whether autophagy is an upstream regulator of CTGF expression in starved cells, we inhibited autophagy with PtdIns3K inhibitors and evaluated intracellular and extracellular CTGF protein levels. LY294002 (Fig. 4A), 3-MA and wortmannin (Fig. S4) all prevented upregulation of intracellular CTGF protein levels in fibroblasts serum starved for 4 d. CTGF secretion (Fig. 4B) and CTGF mRNA levels (Fig. 4C) were also significantly reduced in fibroblasts serum starved in the presence of LY294002. To further characterize the importance of the autophagic process in regulating CTGF levels, we inhibited autophagy through ATG7 silencing. Again, inhibition of autophagy prevented CTGF upregulation (Fig. 4D). Collectively, these results confirm that autophagy is an upstream regulator of CTGF expression.
Implication of the MTORC1 and MTORC2 pathways in autophagy-induced myofibroblast differentiation
Inhibition of MTOR signaling prevents myofibroblast differentiation in other systems.37 We therefore considered the possibility that MTOR-dependent pathways could be implicated in autophagy-induced myofibroblast differentiation. Phosphorylation of the MTORC1 downstream target RPS6KB138 was rapidly and durably decreased in serum-starved fibroblasts (Fig. 5B and S5A). Phorphorylation of the MTORC2 target AKT at Ser47339 initially decreased upon initiation of serum starvation (Fig. 5A). However, after 2 d of serum starvation, AKT was progressively rephosphorylated at Ser473 (Fig. 5A), suggesting the reactivation of MTORC2 with prolonged starvation.
We then evaluated the impact of rapamycin on phosphorylation of MTORC1 and MTORC2 targets, autophagy, and myofibroblast differentiation. Rapamycin induces autophagy by interacting with FKBP12 leading to MTORC1 inhibition38 whereas long-term exposures to rapamycin can, in certain circumstances, inhibit MTORC2 by preventing formation of new MTORC2 complexes.39,40 In starved and unstarved fibroblasts, rapamycin decreased RPS6KB1 phosphorylation confirming its MTORC1 inhibitory activity (Fig. 5B and S5B) and enhanced autophagy with increased LC3-II/-I ratios or decreased SQSTM1 protein levels (Fig. 5C and S5B). Rapamycin also significantly decreased AKT rephosphorylation at Ser473 in fibroblasts that were serum starved for longer than 2 d (Fig. 5B) whereas, in unstarved fibroblasts, rapamycin did not reduce and rather enhanced MTORC2 activity, as demonstrated with increased AKT phosphorylation (Fig. S5B). This translated into enhanced myofibroblast differentiation with increased expression of CTGF and ACTA2 (Fig. S5B). This result is consistent with previous reports showing that rapamycin preferentially inhibits MTORC1 vs MTORC2 and that MTORC1 blockade can release MTORC1-dependent inhibition of MTORC2.39,41 However, in starved cells, rapamycin decreased MTORC2 activity leading to inhibition of myofibroblast differentiation. Rapamycin prevented the upregulation of both ACTA2 and intracellular CTGF protein levels in serum-starved fibroblasts (Fig. 6A) and also significantly reduced CTGF secretion (Fig. 6B). Serum-starved fibroblasts exposed to rapamycin also showed reduced COL1A1 mRNA level (Fig. 6C) and proCOL1A1 protein level (Fig. S6A). We also exposed starved cells to Torin 1, a dual inhibitor of the MTOR complexes. Torin 1 inhibited MTORC1 and MTORC2 activities, reduced CTGF secretion and ACTA2 and proCOL1A1 synthesis (Fig. S6B, S6C, S6D). Collectively, these results suggest that MTORC2 activity is likely central for autophagy-induced myofibroblast differentiation.
To explore further the importance of MTORC2 activation in autophagy-induced myofibroblast differentiation, RICTOR, an integral component of the MTORC2 complex, was silenced. RICTOR silencing in serum-starved fibroblasts prevented AKT phosphorylation at Ser473 (Fig. 6D). RICTOR silencing also blocked ACTA2 upregulation (Fig. 6D). This was associated with reduced intracellular CTGF protein levels and reduced secretion of CTGF (Fig. 6D, E). Silencing RPTOR, a constituent of the MTORC1 complex, in starved fibroblasts did not modulate ACTA2 and CTGF levels (Fig. S6E). Collectively, these results identify MTORC2 activation as a central regulator of CTGF upregulation and myofibroblast differentiation in serum-starved fibroblasts.
Autophagy is a novel activator of MTORC2-signaling
We then sought to evaluate whether autophagy per se was central to MTORC2 activation in our system. Blocking autophagy in starved fibroblasts with 3-MA, wortmannin or LY294002 significantly reduced phosphorylation of AKT at Ser473 (Fig. 7A), but did not modulate MTORC1 activity (Fig. S7A, S7B). To rule out the possibility that these autophagy inhibitors could directly alter MTORC2 activity independently of autophagy, we also evaluated the impact of ATG7 silencing on Ser473 AKT phosphorylation. ATG7 silencing reduced AKT phosphorylation in starved fibroblasts (Fig. 7B), demonstrating the importance of the autophagic response in triggering MTORC2 activation. Also, in starved fibroblasts silenced for ATG7, transduction with a constitutively active AKT construct enhanced myofibroblast differentiation, with increased protein levels of CTGF and ACTA2 (Fig. S7C). Collectively, these results identify sustained autophagy as a novel activator of MTORC2-dependent signaling leading to enhanced CTGF expression and secretion which in turn fosters myofibroblast differentiation (Fig. 8).
Discussion
Mounting evidence suggests that dysregulated autophagy plays a central role in abnormal repair processes. Fibrosis, a maladaptive form of tissue remodeling, is characterized by the sustained presence of myofibroblasts defined by an enhanced capacity to produce ECM components and to exert a tensile force on the ECM. This leads to ECM thickening and contraction, loss of the normal tissue architecture, and loss of function. Fibrosis characterizes most forms of chronic organ failure including liver cirrhosis,42 renal failure,43 and pulmonary fibrosis.44 Both enhanced and decreased autophagy have been linked to fibrosis, suggesting that the timing of the autophagic process, the cell types at play and the downstream pathways triggered by autophagy weave a complex interplay of responses that may be either beneficial or detrimental to tissue repair. In murine models of liver injury, genetic invalidation of the central autophagic gene ATG7 specifically in hepatic stellate cells prevents their myofibroblast differentiation and significantly decreases liver fibrosis.26 An association between the activation of autophagy and acquisition of myofibroblast markers has also been documented in renal mesangial cells and pulmonary fibroblasts.25,26 However, the use of the MTOR inhibitor rapamycin, a classical inducer of autophagy, in models of renal, pulmonary, and skin fibrosis prevents or decreases fibrotic indices including myofibroblast differentiation.37,45,46 Here, we sought to characterize the pathways linking autophagy with myofibroblast differentiation in stromal cells and to define the various levels of crosstalk between autophagy and MTOR-dependent signaling regulating myofibroblast differentiation. Using starvation as a classical inducer of autophagy in fibroblasts, we demonstrate not only temporal relations between sustained autophagy and myofibroblast differentiation but a central role for autophagy in triggering myofibroblast differentiation. Preventing development of autophagy through inhibition of PtdIns3K with LY294002, wortmannin or 3-MA blocked myofibroblast differentiation. Inhibiting autophagy through ATG7 silencing also prevented myofibroblast differentiation.
Our results demonstrate that in a pure fibroblast system, autophagy enhances myofibroblast differentiation through TGFB-independent pathways. Indeed, we observed no evidence of SMAD signaling in our system. Also, neutralizing antibodies against all active isoforms of TGFB failed to prevent autophagy-induced myofibroblast differentiation while effectively blocking TGFB-induced differentiation. These results do not, however, rule out a potential contribution of TGFB in vivo where the draw of immune cells to the sites of tissue remodeling could accentuate myofibroblast differentiation via TGFB-dependent pathways. Nonetheless, our results demonstrate that in fibroblasts, autophagy triggers an intrinsic program of myofibroblast differentiation largely dependent on the upregulation of CTGF expression and secretion. Several lines of evidence support the central role of CTGF in inducing autophagy-dependent myofibroblast differentiation. Starvation initially decreased CTGF levels but prolonged starvation favored CTGF re-expression. Inhibiting autophagy in starved fibroblasts, either through PtdIns3K inhibition or ATG7 silencing, prevented re-expression of CTGF. Finally, silencing CTGF in starved fibroblasts blocked myofibroblast differentiation.
CTGF is a cysteine-rich 38-kDa member of the CCN early-response gene family that was first described as an important downstream effector of TGFB47 and a potentiator of TGFB's fibrogenic actions.12 Mounting evidence gathered over the past decade has demonstrated that CTGF can initiate fibrogenic responses independently of TGFB.35,36 CTGF is increasingly recognized as a central fibrogenic mediator upregulated in a variety of fibrotic disorders and is overexpressed prior to and in association with fibrosis development.35,36 CTGF acts as a matricellular protein rather than a conventional growth factor, interacting with multidomain structures in association with various cell surface receptors (integrins, proteoglycans, low-density lipoprotein receptor-related protein). CTGF-neutralizing antibodies prevent renal and pulmonary fibrosis48-50 and reduction of CTGF expression by antisense treatment ameliorates renal tubulo-interstitial fibrosis51 and prevents myofibroblast differentiation of hepatic stellate cells.52 In humans, CTGF is upregulated in various chronic fibrotic disorders, including liver fibrosis, systemic sclerosis, diabetic nephropathy, and chronic allograft nephropathy.17,53-58
Our results also highlight the central importance of MTORC2 in autophagy-induced myofibroblast differentiation. In our system, phosphorylation of the MTORC1 downstream target RPS6KB1 was low in starved fibroblasts and exposure to rapamycin or Torin 1 further reduced RPS6KB1 phosphorylation. The pattern of MTORC2 activation in starved fibroblasts, monitored by AKT phosphorylation at serine 473, was quite distinct. As expected, AKT phosphorylation rapidly decreased upon starvation but was followed by spontaneous rephosphorylation after 2 d. In starved cells, blocking MTORC2 activity, with rapamycin, Torin 1 or RICTOR silencing, prevented myofibroblast differentiation. In unstarved cells, however, rapamycin inhibited MTORC1 and triggered autophagy, but failed to reduce AKT phosphorylation. In this context, rapamycin treatment enhanced MTORC2 activity and enhanced myofibroblast differentiation. These results are consistent with previous reports showing that rapamycin preferentially inhibits MTORC1 vs MTORC2 and that MTORC1 blockade can release MTORC1-dependent inhibition of MTORC2.39,41 However, in a situation where MTORC1 activity is absent, such as starvation, prolonged rapamycin treatment can display inhibitory activity toward MTORC2.
To further define the importance of autophagy in MTORC2 activation, we inhibited autophagy in starved fibroblasts with inhibitors of PtdIns3K or by silencing ATG7. Both methods concurred in demonstrating a central role for autophagy in MTORC2 activation. Also, when ATG7 silenced starved cells were transduced with a constitutively active AKT construct, myofibroblast differentiation was enhanced. These results demonstrated that MTORC2 is active downstream of autophagy and drives myofibroblast differentiation.
The conventional dogma proposes that MTORC1 regulates mRNA translation and cellular proliferation while MTORC2 activation regulates reorganization of the actin cytoskeleton.40 Our results demonstrate that long-term MTORC2 activation leads to important changes in gene and protein expression patterns in fibroblasts, favoring the development of a fibrogenic microenvironment. These results are in line with recent reports demonstrating that MTORC2 can regulate expression of stress and hypoxia-induced proteins of potential importance in controlling cellular adaptation to external stress.59 Our results further support the notion that MTORC2 can act as an upstream regulator of stress-induced proteins and identify CTGF as a novel downstream product of MTORC2 signaling.
Our results are consistent with the work of Hernandez-Gea V et al., showing that autophagy of hepatic stellate cells enhances liver fibrosis.25,26 Our results may, however, be seen as contradictory to work published by Araya and colleagues demonstrating an inhibitory function for autophagy in myofibroblast differentiation of pulmonary fibroblasts.60 A number of reasons could explain this discrepancy, including differences in duration of autophagy and autophagy inducers. Both studies, however, highlight the importance of MTOR-dependent pathways in controlling myofibroblast differentiation. Also, our work highlights the importance of duration of autophagy on myofibroblast differentiation. In our system, short-term autophagy (up to 24 h) did not activate MTORC2, and failed to increase CTGF secretion and myofibroblast differentiation. Prolonged autophagy, however, induced MTORC2 activation, which in turn promoted CTGF secretion and myofibroblast differentiation (Fig. 8).
In summary, the present results lend further support for a key role for sustained autophagy as a central regulator of myofibroblast differentiation. Long-term starvation, while repressing MTORC1 activation, triggers activation of the MTORC2 complex, culminating in enhanced synthesis and secretion of the fibrogenic mediator CTGF, which in turn initiates a program of myofibroblast differentiation. These results provide novel insights into the fibrogenic molecular pathways triggered by the autophagic program and highlight new potential targets of intervention for preventing maladaptive myofibroblast differentiation.
Materials and Methods
Cell culture
WI-38 human fibroblasts from normal embryonic lung tissue were purchased from the American Type Culture Collection (CCL-75), grown in fibroblast basal medium (Lonza, CC-3131) supplemented with 10% inactivated fetal bovine serum (FBS; Wisent, 090150) (normal medium [N]) and used between passages 6 and 8. Normal human lung fibroblasts (Lonza, CC-2512) and mouse embryonic fibroblasts (ATCC, CRL-2214) were grown in DMEM (Wisent, 319-005-CL) with 10% FBS. For growth factor deprivation, the fibroblasts were washed twice with phosphate-buffered saline (PBS; Wisent, 311-425-CL) before being exposed to serum-free medium. The media were replaced every other day. Conditioned cell culture media were centrifuged at 1,200 g for 15 min at 4°C and kept at −20°C for further analysis. The cells were plated at a density of 20,000 cells/cm2 in 6-well plates and exposed to experimental conditions or vehicle when they reached 80–90% confluency.
Immunoblotting
Cellular proteins were extracted, separated by electrophoresis, transferred to nitrocellulose membranes and probed, as described previously.19,32,61 To compare levels of secreted proteins, 3 ml of conditioned medium were concentrated by centrifugation in a 5,000 molecular weight cut-off Vivaspin 500 system (Sartorius Stedim Biotech, VS0112) at 15,000 g, followed by electrophoresis and protein gel blotting (WB). The antibodies used for WB were anti-ACTA2/αSMA (Sigma-Aldrich, A2547), anti-CTGF (Santa Cruz Biotechnology, sc-14939), anti-LC3B (Novus, NB600-1384), anti-mouse SQSTM1/p62 (MBL, PM045B), anti-human SQSTM1/p62 (Cell Signaling Technology, 8025), anti-phospho-RPS6KB1/p70S6K (Thr389; Cell Signaling Technology, 9205), anti-phospho-AKT (Ser473; Cell Signaling Technology, 9271) and anti-AKT (Cell Signaling Technology, 9272), anti-RICTOR (Cell Signaling Technology, 2114), anti-RPTOR (Cell Signaling Technology, 2280), anti-PARP (Cell Signaling Technology, 9542), anti-phospho-SMAD2 (Millipore, AB3849) and anti-SMAD2/3 (Millipore, 07-408), anti-proCOL1A1/collagen type I (Meridian, T59103R), anti-ATG7 (R&D Systems, MAB6608), and anti-HA (Roche Applied Science, 11 666 606 001). Membranes were stained with Ponceau S Red (Sigma, P-3504) as loading control, or, alternatively, after initial probing, they were stripped and re-probed with anti-α-tubulin (Calbiochem, CP06). Densitometric analyses were conducted with AlphaImager, version 3.2 (Alpha Innotech Corporation, San Leandro, CA, USA). Data are expressed in arbitrary units.
Immunofluorescence microscopy
Cells were grown in 8-well glass slides (Nalge Nunc, Lab-Tek II 154534), rinsed twice with PBS and fixed with 4% paraformaldehyde. The slides were washed 3 times with PBS before permeabilization and after each subsequent step. Permeabilization was done with 0.1% Triton X-100 (Sigma, T9284) in PBS for 15 min. Chamber slides were blocked with PBS/10% donkey serum (Sigma, D9663)/1% BSA (Sigma, A9647)/0.1% Tween 20 (Sigma, P1379) for 15 min. For ACTA2 staining, cells were incubated with mouse monoclonal antibody (Sigma-Aldrich, A2547) and Alexa 594-labeled anti-mouse Ab (Molecular Probes, A21203), each for 60 min at room temperature in blocking buffer. For stress fiber characterization, the slides were incubated with phalloidin-FITC (Sigma-Aldrich, P5282) for 60 min at room temperature in blocking buffer. Nuclei were stained with TO-PRO 3 (Molecular Probes, T3605). The cells were then visualized under a Leica SP5 confocal microscope and analyzed with Leica LAS AF software (Leica Microsystems, Concord, ON, Canada).
GFP-LC3B expression
We used the Premo Autophagy Sensor GFP-LC3B BacMam 2.0 Expression vector Kit from Invitrogen (P36235) and followed instructions provided by the manufacturer. In brief, WI-38 fibroblasts were plated in 8-well glass slides (Nalge Nunc, Lab-Tek II 154534). When they reached 40,000 cells/well, they were infected with GFP-LC3B-containing baculovirus at a multiplicity of infection of 30 in normal medium. After overnight incubation, the slides were washed twice with PBS and exposed to experimental conditions for 24 h. The cells were then fixed with paraformaldehyde (4%) and nuclei were stained with 0.5 ug/ml DAPI (Invitrogen, D3571). Cells were observed using a Olympus multiphoton FV-1000 MER confocal microscope.
Small interfering RNAs (siRNAs)
For silencing of CTGF, WI-38 fibroblasts were plated in 6-well plates at 20,000 cells per cm2. When the cells were near confluency, they were transfected with oligofectamine (6 μl/well; Invitrogen, 12252-011) and siRNAs at a final concentration of 200 nM annealed oligonucleotides in cell culture medium without serum. Two d post-transfection, the medium was changed and the cells were maintained under experimental conditions (without serum) for 5 d, with medium changed every 2 d, followed by evaluation of myofibroblast differentiation. Pre-designed oligonucleotides for human CTGF (ON-TARGETplus SMARTpool L-012633-01) and control siRNA (ON-TARGETplus non-targeting siRNA D-001810-01) were obtained from Dharmacon Research and Thermo Fisher Scientific.
For ATG7, RICTOR, and RPTOR silencing, fibroblasts grown in normal conditions were harvested by trypsinization and separated in aliquots of 1.5 million cells. Separate aliquots were transfected with siRICTOR (Dharmacon, L-016984-00), siATG7 (Dharmacon, L-020112-00), siRPTOR (Dharmacon, L-004107-00), or siControl (Dharmacon, D-001810-03). We used the Amaxa Nucleofector electroporator (Amaxa, Gaithersburg, MD, USA) and the Nucleofector electroporation kit for WI-38 (Lonza, VCA-1001) according to the manufacturer's guidelines. The final concentration of siRNA was 150 pmol of siRNA/reaction. After electroporation, each cellular aliquot was plated in 2 wells of a 6-well plate in normal medium for 24 h. The media were then changed for experimental condition (medium without serum) after 2 washes with PBS. The cells were harvested at different time points for western blot analysis. For 4 d in SS, the media were changed at d 2.
Adenoviral vector system for overexpression of constitutively active AKT
For activation of AKT, WI-38 fibroblasts were infected with an adenovirus vector encoding a constitutively active AKT construct (Ad-CA-AKT [Myr], Vector Biolabs, 1020). A commercially available adenovirus vector (Ad-CMV-null, Vector Biolabs, 1300) was used as control. Cells were infected at a multiplicity of infection of 2 in normal medium for 6 h, followed by electroporation with siATG7 or control, as described above.
RNA preparation and quantitative polymerase chain reaction (qPCR)
Total RNA from WI-38 fibroblasts was prepared with the RNeasy kit from Qiagen Inc. (74134). cDNA synthesis was completed according to the M-MLV-RT First-Strand Synthesis protocol (Invitrogen, 28025-013) with a starting amount of 1 μg RNA and reverse transcription with random hexamers (Invitrogen, 48190-011). PCR was performed with a Rotor-gene 3000 Real-Time Centrifugal DNA Amplification System (Corbett Tumor Tissues Research, Sydney, Australia). Quantitect™ SYBR Green PCR (Qiagen, 204143) reaction mixture was employed according to the manufacturer's instructions. Serial dilutions generated a standard curve for each gene tested, to define the efficiency of real time qPCR. All experiments, including positive and negative controls, were run in triplicate. The primer sequences were: CTGF fw 5′- TTGGCCCAGACCCAACTATG, rev 5′-CAGGAGGCGTTGTCATTGGT; COL1A1 fw 5′- CCTCAAGGGCTCCAACGAG, rev 5′ TCAATCACTGTCTTGCCCCA; COL3A1 fw 5′- AACACGCAAGGCTGTGAGACT, rev 5′- GCCAACGTCCACACCAAATT; GAPDH fw 5′- TGCACCACCAACTGCTTAGC, rev 5′- GGCATGGACTGTGGTCATGAG.
Reagents
Recombinant human TGFB1 (100-B), pan-TGFB1/2/3-blocking antibody (AB-100-NA) and isotype controls (AB-105-C) were obtained from R&D Systems. LY294002 (440202) and 3-methyladenine (189490) were purchased from Calbiochem, and rapamycin (R0395), wortmannin (W3144) and bafilomycin A1 (B1793) from Sigma. Torin 1 (4247) was obtained from TOCRIS bioscience. All other reagents were from Sigma Chemicals.
Statistical analysis
The results, expressed as means ± SEM, were analyzed by unpaired Student t test or the Mann-Whitney test as appropriate. P < 0.05 was considered significant for all tests.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Funding
This work was supported by research grants from the Canadian Institutes of Health Research (CIHR, MOP-123436) to MJH, holder of the Shire Chair in Nephrology, Transplantation and Renal Regeneration of the Université de Montréal. MJH is supported by the Canadian Transplant Research Program (CNTRP). MB is the recipient of a fellowship from Fonds de la recherche en santé du Québec (FRQS). The authors thank the J.-L. Lévesque Foundation for renewed support.
Supplemental Material
Supplemental data for this article can be accessed on the publisher's website.
References
- 1. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007; 127:526-37; PMID:17299435; http://dx.doi.org/ 10.1038/sj.jid.5700613 [DOI] [PubMed] [Google Scholar]
- 2. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117:524-9; PMID:17332879; http://dx.doi.org/ 10.1172/JCI31487 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Bio 2002; 3:349-63; http://dx.doi.org/ 10.1038/nrm809 [DOI] [PubMed] [Google Scholar]
- 4. Hinz B, Gabbiani G. Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives. F1000 Biol Rep 2010; 2:78; PMID:21170369; http://dx.doi.org/ 10.3410/B2-78 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Desmouliere A, Darby IA, Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab Invest 2003; 83:1689-707; PMID:14691287; http://dx.doi.org/ 10.1097/01.LAB.0000101911.53973.90 [DOI] [PubMed] [Google Scholar]
- 6. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-beta signaling in fibrosis. Growth Factors 2011; 29:196-202; PMID: ; http://dx.doi.org/1697606 10.3109/08977194.2011.595714 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T. Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990; 86:917-22; PMID:1697606; http://dx.doi.org/ 10.1172/JCI114793 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Boor P, Floege J. Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol 2011; 38:441-50; PMID:21276040; http://dx.doi.org/ 10.1111/j.1440-1681.2011.05487.x [DOI] [PubMed] [Google Scholar]
- 9. Sime PJ, O’Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001; 99:308-19; PMID:11358425; http://dx.doi.org/ 10.1006/clim.2001.5008 [DOI] [PubMed] [Google Scholar]
- 10. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7:d793-807; PMID:11897555; http://dx.doi.org/ 10.2741/gressner [DOI] [PubMed] [Google Scholar]
- 11. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol 1999; 181:153-9; PMID:10457363; http://dx.doi.org/ 10.1002/(SICI)1097-4652(199910)181:1%3c153::AID-JCP16%3e3.0.CO;2-K [DOI] [PubMed] [Google Scholar]
- 12. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002; 4:599-604; PMID:12134160 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996; 107:404-11; PMID:8751978; http://dx.doi.org/ 10.1111/1523-1747.ep12363389 [DOI] [PubMed] [Google Scholar]
- 14. Leask A, Parapuram SK, Shi-Wen X, Abraham DJ. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal 2009; 3:89-94; PMID:19156539; http://dx.doi.org/ 10.1007/s12079-009-0037-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Liu S, Shi-wen X, Abraham DJ, Leask A. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum 2011; 63:239-46; PMID:20936632; http://dx.doi.org/ 10.1002/art.30074 [DOI] [PubMed] [Google Scholar]
- 16. Phanish MK, Winn SK, Dockrell ME. Connective tissue growth factor-(CTGF, CCN2)–a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol 2010; 114:e83-92; PMID:19955828; http://dx.doi.org/ 10.1159/000262316 [DOI] [PubMed] [Google Scholar]
- 17. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996; 106:729-33; PMID:8618012; http://dx.doi.org/ 10.1111/1523-1747.ep12345771 [DOI] [PubMed] [Google Scholar]
- 18. Huang G, Brigstock DR. Regulation of hepatic stellate cells by connective tissue growth factor. Front Biosci (Landmark Ed) 2012; 17:2495-507; PMID:22652794; http://dx.doi.org/ 10.2741/4067 [DOI] [PubMed] [Google Scholar]
- 19. Laplante P, Sirois I, Raymond MA, Kokta V, Beliveau A, Prat A, Pshezhetsky AV, Hebert MJ. Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis. Cell Death Differ 2010; 17:291-303; PMID:19730442; http://dx.doi.org/ 10.1038/cdd.2009.124 [DOI] [PubMed] [Google Scholar]
- 20. Hong KH, Yoo SA, Kang SS, Choi JJ, Kim WU, Cho CS. Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clin Exp Immunol 2006; 146:362-70; PMID:17034590; http://dx.doi.org/ 10.1111/j.1365-2249.2006.03199.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol 2004; 287:F1223-32; PMID:15315937; http://dx.doi.org/ 10.1152/ajprenal.00245.2004 [DOI] [PubMed] [Google Scholar]
- 22. Braig S, Wallner S, Junglas B, Fuchshofer R, Bosserhoff AK. CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer 2011; 105:231-8; PMID:21673687; http://dx.doi.org/ 10.1038/bjc.2011.226 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Nazio F, Strappazzon F, Antonioli M, Bielli P, Cianfanelli V, Bordi M, Gretzmeier C, Dengjel J, Piacentini M, Fimia GM, et al. . mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol 2013; 15:406-16; PMID:23524951; http://dx.doi.org/ 10.1038/ncb2708 [DOI] [PubMed] [Google Scholar]
- 24. Del Principe D, Lista P, Malorni W, Giammarioli AM. Fibroblast autophagy in fibrotic disorders. J Pathol 2013; 229:208-20; PMID:23018629; http://dx.doi.org/ 10.1002/path.4115 [DOI] [PubMed] [Google Scholar]
- 25. Hernandez-Gea V, Friedman SL. Autophagy fuels tissue fibrogenesis. Autophagy 2012; 8:849-50; PMID:22617442; http://dx.doi.org/ 10.4161/auto.19947 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, Czaja MJ, Friedman SL. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 2012; 142:938-46; PMID:22240484; http://dx.doi.org/ 10.1053/j.gastro.2011.12.044 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. . Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/ 10.4161/auto.19496 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, Ong CN, Codogno P, Shen HM. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 2010; 285:10850-61; PMID:20123989; http://dx.doi.org/ 10.1074/jbc.M109.080796 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Blommaart EF, Krause U, Schellens JP, Vreeling-Sindelarova H, Meijer AJ. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem 1997; 243:240-6; PMID:9030745; http://dx.doi.org/ 10.1111/j.1432-1033.1997.0240a.x [DOI] [PubMed] [Google Scholar]
- 30. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3′-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 2000; 275:992-8; PMID:10625637; http://dx.doi.org/ 10.1074/jbc.275.2.992 [DOI] [PubMed] [Google Scholar]
- 31. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, et al. . Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005; 169:425-34; PMID:15866887; http://dx.doi.org/ 10.1083/jcb.200412022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AMJ, Langelier Y, Bernard M, Raymond Y, Hebert MJ. Novel fibrogenic pathways are activated in response to endothelial apoptosis: Implications in the pathophysiology of systemic sclerosis. J Immunol 2005; 174:5740-9; PMID:15843576; http://dx.doi.org/ 10.4049/jimmunol.174.9.5740 [DOI] [PubMed] [Google Scholar]
- 33. Laplante P, Raymond MA, Labelle A, Abe J, Iozzo RV, Hebert MJ. Perlecan proteolysis induces an alpha2beta1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation. J Biol Chem 2006; 281:30383-92; PMID:16882656; http://dx.doi.org/ 10.1074/jbc.M606412200 [DOI] [PubMed] [Google Scholar]
- 34. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113:685-700; PMID:12809600; http://dx.doi.org/ 10.1016/S0092-8674(03)00432-X [DOI] [PubMed] [Google Scholar]
- 35. Leask A. CCN2: a bona fide target for anti-fibrotic drug intervention. J Cell Commun Signal 2011; 5:131-3; PMID:21484186; http://dx.doi.org/ 10.1007/s12079-011-0125-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Brigstock DR. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signal 2010; 4:1-4; PMID:19798591; http://dx.doi.org/ 10.1007/s12079-009-0071-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PloS One 2012; 7:e33626; PMID:22470459; http://dx.doi.org/ 10.1371/journal.pone.0033626 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2:222-32; PMID:12878853; http://dx.doi.org/ 10.4161/cbt.2.3.360 [DOI] [PubMed] [Google Scholar]
- 39. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and AktPKB. Mol Cell 2006; 22:159-68; PMID:16603397; http://dx.doi.org/ 10.1016/j.molcel.2006.03.029 [DOI] [PubMed] [Google Scholar]
- 40. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93; PMID:22500797; http://dx.doi.org/ 10.1016/j.cell.2012.03.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Julien LA, Carriere A, Moreau J, Roux PP. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 2010; 30:908-21; PMID:19995915; http://dx.doi.org/ 10.1128/MCB.00601-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117:539-48; PMID:17332881; http://dx.doi.org/ 10.1172/JCI30542 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21:1819-34; PMID:20864689; http://dx.doi.org/ 10.1681/ASN.2010080793 [DOI] [PubMed] [Google Scholar]
- 44. Sivakumar P, Ntolios P, Jenkins G, Laurent G. Into the matrix: targeting fibroblasts in pulmonary fibrosis. Curr Opin Pulm Med 2012; 18:462-9; PMID:22847104; http://dx.doi.org/ 10.1097/MCP.0b013e328356800f [DOI] [PubMed] [Google Scholar]
- 45. Patel AS, Lin L, Geyer A, Haspel JA, An CH, Cao J, Rosas IO, Morse D. Autophagy in idiopathic pulmonary fibrosis. PloS one 2012; 7:e41394; PMID:22815997; http://dx.doi.org/ 10.1371/journal.pone.0041394 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, et al. . Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010; 62:2476-87; PMID:20506342; http://dx.doi.org/ 10.1002/art.27498 [DOI] [PubMed] [Google Scholar]
- 47. Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 1996; 7:469-80; PMID:9052988 [PubMed] [Google Scholar]
- 48. Ponticos M, Holmes AM, Shi-wen X, Leoni P, Khan K, Rajkumar VS, Hoyles RK, Bou-Gharios G, Black CM, Denton CP, et al. . Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum 2009; 60:2142-55; PMID:19565505; http://dx.doi.org/ 10.1002/art.24620 [DOI] [PubMed] [Google Scholar]
- 49. Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 2012; 5 Suppl 1:S24; PMID:23259531; http://dx.doi.org/ 10.1186/1755-1536-5-S1-S24 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, Brenner M, Guo G, Zhang W, Oliver N, et al. . Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011; 4:4; PMID:21284856; http://dx.doi.org/ 10.1186/1755-1536-4-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, et al. . Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004; 15:1430-40; PMID:15153554; http://dx.doi.org/ 10.1097/01.ASN.0000130565.69170.85 [DOI] [PubMed] [Google Scholar]
- 52. Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S, Zhou H, Lu H, Jin Y. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006; 8:889-900; PMID:16652398; http://dx.doi.org/ 10.1002/jgm.894 [DOI] [PubMed] [Google Scholar]
- 53. Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999; 21:693-700; PMID:10572066; http://dx.doi.org/ 10.1165/ajrcmb.21.6.3719 [DOI] [PubMed] [Google Scholar]
- 54. Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, Gauthier JM, Ba N, Sobesky R, Ratziu V, et al. . Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999; 30:968-76; PMID:10498649; http://dx.doi.org/ 10.1002/hep.510300425 [DOI] [PubMed] [Google Scholar]
- 55. Sato S, Nagaoka T, Hasegawa M, Tamatani T, Nakanishi T, Takigawa M, Takehara K. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27:149-54; PMID:10648031 [PubMed] [Google Scholar]
- 56. Metalidis C, van Vuuren SH, Broekhuizen R, Lerut E, Naesens M, Bakker SJ, Wetzels JF, Goldschmeding R, Kuypers DR. Urinary connective tissue growth factor is associated with human renal allograft fibrogenesis. Transplantation 2013; 96:494-500; PMID:23803600; http://dx.doi.org/ 10.1097/TP.0b013e31829b07e1 [DOI] [PubMed] [Google Scholar]
- 57. Cheng O, Thuillier R, Sampson E, Schultz G, Ruiz P, Zhang X, Yuen PS, Mannon RB. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 2006; 6:2292-306; PMID:16889607; http://dx.doi.org/ 10.1111/j.1600-6143.2006.01493.x [DOI] [PubMed] [Google Scholar]
- 58. Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, van Nieuwenhoven FA. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006; 29:83-8; PMID:16373901; http://dx.doi.org/ 10.2337/diacare.29.01.06.dc05-1670 [DOI] [PubMed] [Google Scholar]
- 59. Nayak BK, Feliers D, Sudarshan S, Friedrichs WE, Day RT, New DD, Fitzgerald JP, Eid A, Denapoli T, Parekh DJ, et al. . Stabilization of HIF-2alpha through redox regulation of mTORC2 activation and initiation of mRNA translation. Oncogene 2013; 32:3147-55; PMID:22869144; http://dx.doi.org/ 10.1038/onc.2012.333 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Araya J, Kojima J, Takasaka N, Ito S, Fujii S, Hara H, Yanagisawa H, Kobayashi K, Tsurushige C, Kawaishi M, et al. . Insufficient autophagy in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2013; 304:L56-69; PMID:23087019; http://dx.doi.org/ 10.1152/ajplung.00213.2012 [DOI] [PubMed] [Google Scholar]
- 61. Cailhier JF, Sirois I, Laplante P, Lepage S, Raymond MA, Brassard N, Prat A, Iozzo RV, Pshezhetsky AV, Hebert MJ. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J Biol Chem 2008; 283:27220-9; PMID:18658137; http://dx.doi.org/ 10.1074/jbc.M801164200 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.